Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 34.00p 4,788 06:33:58
Bid Price Offer Price High Price Low Price Open Price
32.00p 36.00p 34.00p 34.00p 34.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.7 -7.9 -9.3 - 23.46

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-05-24 15:23:3032.10380121.98O
2018-05-24 14:52:1933.301,000333.00O
2018-05-24 13:37:4232.013,000960.30O
2018-05-24 13:29:5233.75408137.68O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
24/5/2018
09:20
Avacta Daily Update: Avacta is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 34p.
Avacta has a 4 week average price of 29.50p and a 12 week average price of 29.50p.
The 1 year high share price is 96.50p while the 1 year low share price is currently 29.50p.
There are currently 68,989,487 shares in issue and the average daily traded volume is 108,753 shares. The market capitalisation of Avacta is £23,456,425.58.
14/5/2018
21:06
escapetohome: Come on now avacta this is silly, what does this sort of share price say about the running of the company?? Not good. I would get it sorted. Thats my very strong advice indeed. Nudge Nudge Wink Wink!!!!
29/3/2018
09:42
lantanatony: We need some proper Brokers,capable of supporting the share price. Let's also hope IP Group are the seller as we need them to reduce their influence. But most of all we need a deal with revenue attached.
18/3/2018
22:13
lantanatony: You may think,that I keep going about the Avacta brokers. But let me point out once again that when they were appointed,Avacta shares were around one pound. Furthermore,as market makers they seem happy to preside over any dramatic drop in the share price ,even on the sale of just a small amount of shares. Yet their Analysts are still predicting a Two pound share price! Talk about a "Toffee shop ". No that's unfair on Toffee Shops! Meanwhile,Avacta keep announcing hopeful information,but no meaningful revenue streams to support them. How could anyone realistically believe that this is a company capable of clinical drug development? Watch out for IP Group loading up Avacta with their next best idea. Then another speculative fundraising. Unfortunately,it's a very sad story. The Avacta Board need to examin their Corporate responsibility. You can not keep telling shareholders that you are going into clinical Development without a creditable structure and of course the finance.......can you?
10/3/2018
23:04
lantanatony: Why,no statement from the company on the dramatic fall in the share price ?
11/12/2017
11:06
dec2000: Firstly thanks to biotechgeek for his post which hopefully can start a good conversation. And of course his conclusion that the market will decide is also absolutely correct. He approaches the problem from the point of view of production.. and points out that the three main ways of producing affinity ligands are through synthetic chemistry, phage display and in vivo and goes on to point out that Avacta have “simply” made phage display work with a particular type of protein and they have chosen one that is particularly robust. In my belief this is accurate but also undersells what Avacta have achieved and what they are attempting to achieve. In my belief the production issue is not the most important concern.. what is of real significance is what Avacta are hoping to achieve through the use of this technology. The usefulness of any affinity ligand depends partly on the ligand and also what it is attached to and also what you are trying to use it for. In other words there are horses for courses. Indeed that is what Avacta have said : they are not interested in displacing the role of antibodies generally rather finding some alternatives which work better than antibodies in certain circumstances and they have effectively segmented their market into two : diagnostics and research reagents (the so called RxDx market) and the therapeutics market (the Tx market) . In the RxDx market there is massive competition but there are some advantages that Affimers can bring including ease of developing affinity ligands, small molecular size and stability as well as exquisite sensitivity. Of course they compete against phage-display produced antibodies and others, but they do have advantages themselves and other protein scaffolds have not entered the RxDx territory. The proof of this particular pudding does lie in the eating, but they are generating lots of sales leads and have indeed signed a deal with a top 3 diagnostics company… so it can’t be all bad! The question is - can they carve out for themselves a sensibly sized slice of this particular market? With regard to therapeutics, they have deliberately gone for a differentiated strategy which builds on the differences and advantages of Affimers which seems to me to be reasonable. They are using the ability of Affimers to link with themselves to make multimeric molecules which have significant potential uses as T cell recruiters and combination therapies (which might be more therapeutically effective and also more cost effective), they are using the stability of the cystatin molecule to develop drug conjugates with Glythera (also an IP company) which effectively add, say, a poison to the Affimer molecule to be able to selectively kill unwanted cells such as cancer cells; and they are using the simplicity of the cystatin protein and its ease of expression in cells in gene therapy approaches with Moderna. That sounds to me like a sensible approach and not to be denigrated. Whether it works or not of course is the question and why the shares are currently lowly rated. If any of the above are proved to work then the share price will be much higher. As biotechgeek says : the market will decide.
10/12/2017
19:43
lantanatony: Tradernick is spot on and my point is that the likes of Finncap won't be able to raise the required capital. The share price reflects that the market is not convinced. Sadly the take up for Affimers so far has been disappointing and positive news flow in now critical.
08/11/2017
20:54
lantanatony: No support from for the share price from the market or our Brokers even at this low share price. Meanwhile, there seems to be at least one substantial seller about. Therefore, what is the point of our CEO presenting at a Finncap event this month when the hosts are not convinced? I have to ask, what party is insisting on the confidentiality in the deals that Avacta have published? Could it be Avacta are wanting to hide from the deal detail?! Can the whole Big Pharma investing sector be wrong to ignore Avacta? The share price says it all.
04/10/2017
17:11
danatkins: Drewster yes I was thinking on these lines also. Any developments re groundbreaking therapeutics would multiple the share price and very quickly. Also another reason why Avacta could be bought. Just my opinion. Personally of any success I'd like to see expansion of the co.
04/10/2017
12:27
the drewster: One day it will either give up, be sold in a fire sale, or be ten to one hundred times the share price. Risk reward profile is for each individual speculator to decide.
30/11/2016
18:41
dec2000: Yet Finncap yesterday placed a value on AVACTA of 200p in 12 months! Avacta Group PLC (LON:AVCT) Issued With ‘CorporateR17; Rating At FinnCap By Warren Smith / in UK Broker Ratings / on Wednesday, 30 Nov 2016 02:02 PM / 0 Comments Following an update released by analysts at finnCap on Tuesday the broker has now set a ‘CorporateR17; rating on shares of Avacta Group PLC (LON:AVCT) with a price target of 200. On Tuesday finnCap reiterated its target for shares of Avacta Group PLC as ‘CorporateR17; recommending a target price of 200 for investors; potentially meaning there is an increase of 129.75% from Avacta Group PLC’s share price of 87.05. Avacta Group PLC has 68,287,000 shares currently held by shareholders which currently trade around the 87.05 mark which totals Avacta Group PLC’s market capitalisation to 59.44M GBP. 12 Month Share Chart For Avacta Group PLC LON:AVCT In the duration of 12 months Avacta Group PLC’s share price has increased by 0% to 87.05 from 0.00. The business has a 50 day moving average of 89.99 and a 200 day moving average of 95.94 whilst the 52 week high shares of Avacta Group PLC have reached is 134.5 and the 52 week low is 83.02. Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and develoPment
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180525 05:30:53